Sign in
CompletedPhase 3

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Key facts

Who runs it
Basilea Pharmaceutica
Where
Evanston and Morgantown, United StatesSee the 2 sitesAlso in 7 other countries, 12 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
9 people enrolled
Started
6 Aug 2023
Ended
18 Dec 2024
Type of study
Interventional
Treatments tested
  • Ceftobiprole medocaril
Record updated
28 July 2025

Who can take part

Age
3 days to 3 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Informed consent from parent(s) or other legally acceptable representative (LAR) to participate in the study
  • Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3 days to ≤ 3 months
  • Diagnosis of documented or presumed bacterial LOS requiring administration of systemic antibiotic treatment
  • Sufficient vascular access to receive study drug and to allow blood sampling at a site separate from the study drug infusion line

Who cannot take part

  • Use of systemic antibacterial therapy for longer than 72 hours within 7 days before start of study medication
  • Participation in another clinical study with an investigational product within 30 days of enrollment in the current study
  • Proven central nervous system infection (e.g., meningitis, brain abscess)
  • Progressively fatal underlying disease, or life expectancy < 30 days
  • Impaired renal function or known significant renal disease, as evidenced by an estimated glomerular filtration rate (using the Schwartz formula or other applicable formula) calculated to be less than 2/3 of normal for the applicable age group, OR urinary output < 0.5 mL/kg/h (measured over at least 8 hours), OR requirement for dialysis
  • Refractory septic shock not responding to 60 minutes of vasopressor treatment within 48 hours before enrollment
  • Proven ventilator-associated pneumonia
  • Proven osteomyelitis, infective endocarditis, or necrotizing enterocolitis

Where in United States

Also in 7 other countries, 12 sites

  • NorthShore University HealthSystem-Evanston HospitalEvanston, United States
  • West Virginia UniversityMorgantown, United States

About the trial

What the trial wants to find out

This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.

The group in the trial

  • Treatment Arm: CeftobiproleTreatment being tested

    Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg

    Treatment: Ceftobiprole medocaril

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Single-arm, Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Ceftobiprole Medocaril in Term and Pre-term Neonates and Infants up to 3 Months of Age With Late-onset Sepsis
Record updated
28 July 2025